Delayed London S.E. 04:43:43 2024-06-24 am EDT 5-day change 1st Jan Change
17 GBX -2.86% Intraday chart for Renalytix Plc -2.86% +9.68%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Renalytix's Diabetes, Kidney Disease Test Gets Medicare Final Coverage Determination MT
Renalytix Secures Medicare's Final Local Coverage Determination for Kidney Disease Test MT
Shares in Renalytix jump as Medicare issues LCD for kidneyintelX.dkd AN
Certain Ordinary Shares of Renalytix Plc are subject to a Lock-Up Agreement Ending on 11-JUN-2024. CI
Renalytix Files Registration Statement on Behalf of Selling Shareholders MT
EXECUTIVE CHANGES: Resolute Mining hires former Acacia exec as chair AN
Renalytix Plc Designates Joel R. Jung as Principal Accounting Officer CI
Renalytix CFO Steps Down; Interim Successor Named MT
Renalytix plc Announces Chief Financial Officer Changes CI
Renalytix Plans to Sell American Depositary Shares for Up to $15 Million MT
Vertu Motors ups dividend as hails record revenue AN
Transcript : Renalytix Plc, Q3 2024 Earnings Call, May 15, 2024
Earnings Flash (RNLX) RENALYTIX Reports Q3 Revenue $535,000 MT
Renalytix Plc Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
Renalytix Plc Reports Impairment Loss on Property, Equipment and Other Long-Lived Assets for the Third Quarter Ended March 31, 2024 CI
Renalytix chief business officer to become president AN
Renalytix Names Chief Business Officer as President MT
Renalytix plc Announces Executive Changes, Effective from April 30, 2024 CI
Renalytix Issues New Shares for Convertible Bonds Repayment MT
FTSE 100 Index Closes Up 0.4% Lifted by Miners DJ
Renalytix announces financing of up to USD4 million AN
Renalytix to Raise Up to $4 Million via Share Offering MT
Renalytix plc Announces Change of Registered Office Address CI
Horizonte subsidiary hit with debt injunction AN
Renalytix plc's KidneyIntelX Included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease CI
Chart Renalytix Plc
More charts
Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. It is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. RENX Stock
  4. News Renalytix Plc
  5. Renalytix Plans to Sell American Depositary Shares for Up to $15 Million